VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

(2015) John R. Mackey et al.   JOURNAL OF CLINICAL ONCOLOGY

A systematic review of bevacizumab efficacy in breast cancer

(2014) Iben Kümler et al.   CANCER TREATMENT REVIEWS

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

(2014) Joseph Gligorov et al.   LANCET ONCOLOGY

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer

(2013) Giuseppe Curigliano et al.   BREAST

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing

(2013) Alberto Ocana et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer

(2013) John P. Crown et al.   JOURNAL OF CLINICAL ONCOLOGY

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

(2013) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

(2013) David Cameron et al.   LANCET ONCOLOGY

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

(2012) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Making Genuine Progress Against Metastatic Breast Cancer

(2012) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Fighting Fire with Fire: Rekindling the Bevacizumab Debate

(2012) Alberto J. Montero et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

(2012) Harry D. Bear et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

(2012) Douglas G. Altman et al.   PLOS MEDICINE

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

(2011) Alberto J. Montero et al.   BREAST CANCER RESEARCH AND TREATMENT

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

(2011) Nicholas J. Robert et al.   Clinical Breast Cancer

Avastin Hearing Leads to More Uncertainty Over Drug's Future

(2011) M. Goozner   JNCI-Journal of the National Cancer Institute

Reputation and Precedent in the Bevacizumab Decision

(2011) Daniel Carpenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers and surrogate end points—the challenge of statistical validation

(2010) Marc Buyse et al.   Nature Reviews Clinical Oncology

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE